Search -

Displaying 121 - 140 of 202

Sort: Relevancy | Date

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

No Benefit of Colchicine in All-Comers PCI

News Conference News AHA 2019

No Benefit of Colchicine in All-Comers PCI

November 17, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

November 16, 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

November 11, 2019

Recurrent Events Common Among Young Patients With CAD

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

Strokes Increasing in STEMI Patients With Cardiogenic Shock

News Conference News TCT 2019

Strokes Increasing in STEMI Patients With Cardiogenic Shock

September 25, 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

September 10, 2019

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

News Conference News EAS 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Michael O'Riordan

May 30, 2019

New Clarity on Patients at High Risk for Bleeding After PCI

News Conference News EuroPCR 2019

New Clarity on Patients at High Risk for Bleeding After PCI

Michael O'Riordan

May 28, 2019

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

Help, Not Harm: Omega-6 PUFAs Linked With Lower Risk of CVD Events

News Daily News

Help, Not Harm: Omega-6 PUFAs Linked With Lower Risk of CVD Events

Michael O'Riordan

April 18, 2019

Flu Vaccination Tied to Less MI in Hospitalized Patients

News Conference News

Flu Vaccination Tied to Less MI in Hospitalized Patients

March 13, 2019

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

News Daily News

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Michael O'Riordan

March 08, 2019

Updated AHA Scientific Statement Addresses CV Risk Reduction in High-Risk Youth

News Daily News

Updated AHA Scientific Statement Addresses CV Risk Reduction in High-Risk Youth

March 05, 2019

TCTMD’s Top 10 Most Popular Stories for February 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for February 2019

March 01, 2019

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Conference News AHA 2018

AHA Puts Focus on the Impact of Violence on Cardiovascular Health

November 14, 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.